Expect near-term stock pressure as the ATM is drawn down; watch daily volume and price action for accelerated selling. The overhang will persist until the full $200M is utilized or the ATM is terminated. No fundamental catalyst offsets this dilution.
Price Chart
Executive Summary
Stoke Therapeutics filed a prospectus supplement to sell up to $200 million of common stock in an at-the-market (ATM) offering through Cantor Fitzgerald. At a $1.8B market cap, this represents ~11% potential dilution, creating near-term selling pressure and a clear negative signal for existing shareholders.
Key Facts
- On August 3, 2026, Stoke filed a prospectus supplement under its existing Sales Agreement with Cantor Fitzgerald for an ATM offering of up to $200 million in common stock.
- The offering is made under the Company's automatic shelf registration statement on Form S-3ASR (File No. 333-294402) filed March 18, 2026.
- Shares may be sold from time to time at market prices, with no fixed timetable or minimum price.
Financial Impact
Up to $200M in new equity, equivalent to ~11% of the $1.8B market cap, resulting in material dilution to existing shareholders.
Risk Factors
- Dilution of ~11% if the full $200M is issued at current prices
- Ongoing overhang from continuous ATM sales may cap upside
- Possible negative signal to market about near-term cash needs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-330804 |
| Document: d135735dex51.htm | 0001193125-26-330804 |
| Document: 0001193125-26-330804-index-headers.html | 0001193125-26-330804 |
| Document: 0001193125-26-330804-index.html | 0001193125-26-330804 |
| Document: 0001193125-26-330804.txt | 0001193125-26-330804 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $33.03 $28.93 | ▼ −12.41% | ▼ −10.46% | $25.91 (−21.56%) |
Aug 3, 2026 8w ago | 8-K | $31.67 $30.89 | ▲ +2.46% | ▲ +1.22% | $25.91 (+18.19%) |
Aug 3, 2026 8w ago | 424B5 | $31.67 $30.89 | ▲ +2.46% | ▲ +1.22% | $25.91 (+18.19%) |
Jun 30, 2026 13w ago | 8-K | $32.72 $29.31 | ▼ −10.42% | ▼ −9.39% | $25.91 (−20.82%) |
May 7, 2026 21w ago | 8-K | $32.89 $30.01 | ▼ −8.76% | ▼ −8.78% | $25.91 (−21.23%) |
Apr 22, 2026 23w ago | DEFA14A | $34.93 $30.30 | ▼ −13.27% | ▼ −17.90% | $25.91 (−25.83%) |
Apr 7, 2026 25w ago | 8-K | $34.87 $32.96 | ▼ −5.48% | ▼ −14.02% | $25.91 (−25.70%) |
Mar 13, 2026 29w ago | Insider Cluster | $33.19 $35.05 | ▼ −5.60% | ▼ −2.02% | $25.91 (+21.94%) |
Mar 10, 2026 29w ago | Insider Cluster | $38.35 $34.87 | ▼ −9.07% | ▼ −8.92% | $25.91 (−32.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access